|September 29, 2005|
|The sanofi-aventis Group announced today that the United States District Court for the District of New Jersey has set a hearing date for October 27, 2005 on the motion the company filed with Albany Molecular Research, Inc. for a preliminary injunction filed against Barr Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories, Ltd., and Amino Chemicals, Ltd. The motion requests a court order preventing the defendants from marketing unlicensed generic versions of Allegra® (fexofenadine HCl).|
Sanofi-aventis and Albany Molecular Research, Inc. filed the motion on September 20, 2005. The motion was filed after the September 6, 2005 announcement by Barr Pharmaceuticals and Teva Pharmaceuticals that the companies would be collaborating to launch a generic version of Allegra 30 mg, 60 mg and 180 mg.
Sanofi-aventis continues to believe that the generic products of Barr Pharmaceuticals and Teva Pharmaceuticals infringe its intellectual property rights, which are currently the subject of ongoing litigation with the two companies. Sanofi-aventis will continue to vigorously defend its rights.
The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements